Wohin, erneut nur über USD 8.00 oder USD 10.00 oder mehr, Fragen über Fragen....
|
Wohin, erneut nur über USD 8.00 oder USD 10.00 oder mehr, Fragen über Fragen....
wäre schon froh, wenn endlich mal die 6 die 5 vorm Komma dauerhaft ablösen würde... aber auch ich glaube, dass die Investition richtig war... irgendwann kommt der run... auf wieviel auch immer... ;-)
in diesem Sinne allen ein frohes "Kölle Alaaf!" ...
das ist doch was. Und das von unterschiedlichen Gruppen. Da gibt es sicher Erwartungen, die sich im Kurs widerspiegeln. Und zwar vor den Ergebnissen im Sommer. Außerdem hat Sangamo noch mehr in peto...
anliegend ein neuer Bericht zu Sangamo v. 03.03.11
Sangamo (SGMO) Updates on ZFN-Based Treatments for HIV/AIDS
March 3, 2011 7:14 AM EST
Sangamo BioSciences, Inc. (Nasdaq:
) presents data for four ZFN-based therapeutic approaches for the treatment of HIV/AIDS.
From the release:
"The data demonstrate that SB-728-T is well-tolerated with only mild, reversible symptoms typical of infusion reactions. ZFN-CCR5-modified cells exhibited durable engraftment and persistence in the peripheral blood for over a year and behaved like normal, unmodified cells in their ability to traffic to the gut mucosa, an important reservoir of active HIV infection. Demonstration of up to a 45-fold selective expansion of ZFN-CCR5-modified T-cells in this tissue, which represents levels not previously observed in adoptive T-cell approaches, also suggests that the modified cells were resistant to HIV and establish the mechanistic proof of concept for this therapeutic approach. SB-728-T treatment was also demonstrated to improve the overall CD4 T-cell count in all subjects and the CD4:CD8 ratio, a measure of immunologic health, in multiple subjects. In addition, two subjects on a brief 12 week treatment interruption (TI) after SB-728-T treatment showed interesting patterns of HIV RNA appearance and decrease prior to re-institution of HAART. Finally, consistent manufacturing at clinical scale from different manufacturing centers demonstrate that the ZFN-CCR5-modified T-cell process is robust and reproducible."
Main Category:
Also Included In:
;
Pharma Industry / Biotech Industry
Article Date: 04 Mar 2011 - 4:00 PST
Patient / Public: | ||
Healthcare Prof: |
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston from February 27 to March 2, 2011.
"SB-728-T is a key addition to the toolbox of technologies required to move from the bone marrow transplant setting requiring a donor, to the use of the patient's own cells to replicate the 'functional cure' for HIV-infected patients in which one could create and maintain a reservoir of HIV-resistant immune cells," said Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine and an invited speaker at the conference. "The combination of robust and reproducible manufacturing, engraftment, trafficking, persistence and selective expansion of ZFN-CCR5-modified cells set this product apart from all other
therapies tested to date, and is an important step to move from the allogeneic bone marrow transplant setting to the use of the patient's own cells. In particular, the data showing selective expansion and enrichment of SB-728-T in the gut mucosa establishes mechanistic proof of concept that ZFN-CCR5-modified T-cells can constitute a compartment of the immune system that is protected from HIV infection."
In a symposium held on March 2, 2011, Dr. June presented preliminary data from the ongoing investigator-sponsored Phase 1 trial at the University of Pennsylvania as well as data from Sangamo's Phase 1 dose-escalation trial SB-728-902. The presentation included new data from subjects on highly active antiretroviral therapy (HAART) who underwent a treatment interruption (TI) for a specified period after treatment with SB-728-T as well as subjects on HAART with undetectable virus but suboptimal CD4+ T-cell counts (200-500 cells/ mm3).
Clinical Trial Data Summary
The data demonstrate that SB-728-T is well-tolerated with only mild, reversible symptoms typical of infusion reactions. ZFN-CCR5-modified cells exhibited durable engraftment and persistence in the peripheral blood for over a year and behaved like normal, unmodified cells in their ability to traffic to the gut mucosa, an important reservoir of active HIV infection. Demonstration of up to a 45-fold selective expansion of ZFN-CCR5-modified T-cells in this tissue, which represents levels not previously observed in adoptive T-cell approaches, also suggests that the modified cells were resistant to HIV and establish the mechanistic proof of concept for this therapeutic approach. SB-728-T treatment was also demonstrated to improve the overall CD4 T-cell count in all subjects and the CD4:CD8 ratio, a measure of immunologic health, in multiple subjects. In addition, two subjects on a brief 12 week treatment interruption (TI) after SB-728-T treatment showed interesting patterns of HIV RNA appearance and decrease prior to re-institution of HAART. Finally, consistent manufacturing at clinical scale from different manufacturing centers demonstrate that the ZFN-CCR5-modified T-cell process is robust and reproducible.
"Data presented this week at CROI 2011 establish the mechanistic 'proof of concept' of our ZFN-CCR5-modification in autologous T-cells and support broad development of this gene modification approach to HIV therapy," said Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Based on these very encouraging findings, we have recently extended our clinical studies to HIV-infected subjects who are not on HAART, or for whom HAART is no longer effective. This will enable us to comprehensively evaluate SB-728-T across the full spectrum of disease. We look forward to presenting data from all four patient segments later this year."
Abstract #165 Disruption of CCR5 in Zinc Finger Nuclease-treated CD4 T Cells: Phase I Trials (Presenter C. June)
Abstract #46 Successful and Persistent Engraftment of ZFN-M-R5-D Autologous CD4 T Cells (SB-728-T) in Aviremic HIV-infected Subjects on HAART (Presenter J. Lalezari)
Data Presented on Preclinical ZFN-Gene Modification Studies
A third presentation given by invited speaker, Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California (USC), described data from Sangamo's preclinical program to develop CCR-specific ZFNs to modify the gene in hematopoietic
(HSCs) to provide protection of the entire immune system from HIV infection. The work is part of a California Institute for Regenerative Medicine (CIRM) Disease Team Research Award which is funding IND-enabling studies of this approach. Dr. Cannon provided an update on progress in this program, demonstrating that the CCR5 gene of adult HSCs could be efficiently modified with ZFNs with high cell viability. In addition, the ZFN-CCR5-modified HSCs stably engraft in mouse models and retained the ability to develop into the multiple lineages of the immune system.
Abstract #164 CCR5 Knock-out in Hematopoietic Stem Cells (Presenter: P. Cannon)
Data were also presented from Sangamo's ZFN gene-modification program to generate CD4 T-cells that are resistant to so-called "X4-tropic" strains of HIV, strains of HIV that use the CXCR4 co-receptor to infect cells and are characteristic of late-stage HIV infections. This fourth presentation was given by Sangamo's collaborators in the laboratory of Robert Doms, M.D., Ph.D., Chair, Department of Microbiology, the University of Pennsylvania School of Medicine. Disruption of CXCR4 in CD4+ T cells avoids immune system toxicity associated with systemic disruption of the gene. The data demonstrated that ZFN modification of the CXCR4 gene in T-cells results in robust protection of CD4+ T cells from X4-tropic HIV challenge in vitro and confers protection from X4-tropic HIV in humanized mice. Future studies aim to combine CCR5- and CXCR4-ZFNs to totally eliminate HIV co-receptor expression to create completely HIV-resistant CD4+T cells.
Abstract # 47 Creating an HIV-resistant Immune System: Using CXCR4 ZFN to Edit the Human Genome (Presenter C. Wilen)
"Our highly specific gene-modification technology provides a novel platform for the development of transformational ZFP Therapeutics®," said Edward Lanphier, Sangamo's president and CEO. "As these presentations have demonstrated, Sangamo is rapidly advancing a broad pipeline of ZFN-based approaches to HIV/AIDS designed to address the spectrum of the disease. The ground-breaking clinical and preclinical data that we and our collaborators are generating validate our ZFN technology platform for development of novel therapeutic strategies for unmet medical needs, such as HIV and monogenic diseases. The processes and pathways that we have demonstrated in these programs are directly relevant to development of our future ZFP Therapeutics."
Dr. June has no financial relationship with Sangamo BioSciences, Inc.
Source: Sangamo BioSciences, Inc
diese informationsflut ist mal was schönes werden hoffentlich viele aufmerksam auf die aktie :)
aber es ist echt schwer bei den vielen fachausdrücken und abkürzungen das wichtige herauszufiltern :) besonders für techniker die eher nach keep it small & simple arbeiten :)
bin der gleichen Meinung. Ich versuche deswegen bei langen Berichten nur das (für mich Interessante) rauszukopieren, um somit dem Leser das Wesentliche mitzuteilen. Dann gebe ich noch meinen Senf dazu, und natürlich die Quelle, falls ich sie nicht vergesse.
Eigentlich wäre es mir lieber, wenn in den Medien mal estwas mehr Ruhe einkehren würde. Eventuell würde es der Aktie sogar Auftrieb geben. Bei Paion war es doch ähnlich. Ende letzten Jahres gute News, seither gings runter, bis vor wenigen Tagen jedenfalls. Und nun gehts wieder bergauf, ohne News.
Und bei Evotec? Das gleiche Drama. Viele pos. News kamen, die Aktien geht in den Keller. Hoffe, die findet ebenfalls bald wieder Anschluss an ältere Höchststände...
Sorry für den kleinen Exkurs
Wünsche nen guten Start in die ausklingende Karnevalswoche,
ffa
Hoffe, dass die Aktie endlich mal über 8 Dollar steigt und auch bei 8 bleibt! Ich versteh nicht, warum der Titel so gefallen ist...
Grüsse
seit Tagen startet sgmo realtiv stark am Morgen und endet schwaecher am Abend (Nasdaq). Gestern war es umgekehrt.
Vielleicht gibt es ja endlich eine Trendumkehr.
Das Tal der Traenen scheint ueberschritten zu sein. Nach den vielen guten Nachrichten, ist diese nun auch faellig. Wuerde mich wundern, falls 2011 die 10 Euro nicht sehen waeren.
Hallo,
"bis august werden wir sicher die 10 euro sehen", "keine Frage, erreicht wird sie"
30 Prozent Plus bis August? Toll. Und das ganz sicher? Noch toller. Na, dann sollten alle Wissenden alles was sie haben ganz schnell zu Geld machen, dazu noch einen Kredit aufnehmen und alles in Sangamo stecken. Das wird ja ein Riesengeschäft, noch dazu risikolos.
Leider bin ich zu doof, meine Glaskugel richtig zu bedienen. Ich würd auch sooo gern im vorraus wissen, wie sich Aktienkurse entwickeln. Meine Kugel vergisst nur immer, mich rechtzeitig vor Kriegen, Revolutionen, Erdbeben, Zunamis und ähnlichen Dingen zu warnen.
Zum Glück weiß ich ja jetzt, daß bis August nur noch Friede Freude Eierkuchen ist.
es hat ja niemand behauptet dass an einem bestimmten tag der kurs von 10,- erreicht wird, nur BIS august, u das ist immerhin gut möglich bei einer solch volatilen aktie; also verdreh hier nicht die tatsachen und versuch hier nicht klugscheißerisch andere zu belehren.. also echt..
Mit einer kleinen Einschraenkung: falls miese Nachrichten kommen oder die Weltwirtschaft massiv einbricht, wird es kaum was mit der Marke werden. Beide Szenarien erwarte ich allerdings nicht in diesem Jahr
Quelle: FinanzNachrichten.de
Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic DiseasesDUBLINand RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology.
Shire will receive exclusive world-wide rights to ZFP Therapeutics® designed to target four genes (for blood clotting Factors VII, VIII, IX and X) which will be used to investigate curative therapies for hemophilia A and B. Shire also receives the right to designate three additional gene targets. Sangamo is responsible for all activities through submission of Investigational New Drug (IND) Applications and European Clinical Trial Applications (CTA) for each product and Shire will reimburse Sangamo for its internal and external research program-related costs. Shire is responsible for clinical development and commercialization of products arising from the alliance. Shire will pay Sangamo $13 million upfront followed by research, regulatory, development and commercial milestone payments, and royalties on product sales.
"Sangamo's ground-breaking ZFP gene-editing technology will enable us to expand our therapeutic pipeline into therapies for other genetic disorders such as hemophilia," said Sylvie Gregoire, president of Shire's Human Genetic Therapies business. "While still early in the clinical development process, this DNA-binding protein technology is aligned with our focus of developing new treatments that can add value for physicians, patients and their families, and the healthcare community overall."
"We are delighted to be partnering the first of our monogenic disease programs with Shire, a company known for its development of innovative medicines for genetic diseases," said Edward Lanphier, Sangamo's president and chief executive officer. "This alliance is further validation of our ZFP platform as a transformative technology for the development of novel therapeutics, which have the potential to revolutionize the treatment of a wide range of genetic diseases."
Sangamo's ZFP Therapeutic approach utilizes its proprietary ZFP nuclease (ZFN) and ZFP transcription factor (ZFP TF) technology. ZFPs can be engineered to recognize any specific DNA sequence within a gene, and may be applicable to certain Shire therapeutic areas, including hematology and lysosomal storage disorders.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
7 | 663 | Rakete am Start ? | vitalcaffee | Hubertuss | 09.04.24 15:40 | |
27 | Sangamo turnaround in 2023 | Walther Sparbier 2 | Balu4u | 19.02.24 09:39 | ||
3 | 466 | Sangamo: Informationen zu Partner, | farfaraway | boersenhan | 03.07.23 16:31 | |
2 | Sangamo`s banbrechende AID`s HIV Therapie | Magnetfeldfredy | Magnetfeldfredy | 03.10.11 11:28 | ||
2 | 143 | Sangamo Hier geht die Post ab! | Bärenstark | farfaraway | 28.06.11 03:35 |